• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe newsletter
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: E-News

E-News

How healthcare needs to evolve? Learn from 40+ sessions at IHF’s World Hospital Congress

, 26 August 2020/in E-News /by 3wmedia

The 42nd IHF World Hospital Congress, IHF’s cornerstone event, will bring together leaders of national and international hospital and healthcare organizations to share knowledge, expertise and experiences and discuss how healthcare needs to evolve to meet 21st century demands.

Globally health systems are in transition. How do you harness the benefits and overcome the obstacles at this critical point? The Congress will inspire delegates with the journey to date and the opportunities for the future to come.

There are over 40 keynote, plenary panel and concurrent sessions delegates can participate in which will cover value-based care, integrated care and digital transformation.

Value-based healthcare

Prof Elizabeth Teisberg, co-author of “Redefining Health Care: Creating Value-Based Competition on Results”, will open the Congress by sharing insights into the evolution that needs to take place in healthcare. A panel discussion will explore views from health leaders from Hong Kong, Singapore, UK and USA on what 21st century patients demand from healthcare. Concurrent sessions will tackle platforms for value, paying for value and achieving outcomes, the right combination to move from volume to value, among others.

Health system integration
Nigel Edwards, Chief Executive of the Nuffield Trust will share the UK experiences and Nagwa Metwally, Member of Supreme Council of the Egyptian Red Crescent, will talk about patient engagement in Egypt. A panel discussion will explore how we can rethink the role of the hospital in the medical neighborhood. Concurrent sessions will focus on collaboration, health workforce as driver of integrated care, models to support integrated care, partnering and leading in communities and improving health of indigenous peoples.

Impact of technology on healthcare delivery

Charles Alessi, Chief Clinical Officer of HIMSS will provide a big picture and Prof Jeffrey Braithwaite, Foundation Director of the Australian Institute of Health Innovation at Macquarie University will share future predictions for global care. Panelists from around the world will discuss the industry’s bright future. In the concurrent sessions, topics that will be covered include getting the most out of data and intelligence, innovation as a building block for quality and value, hospitals of the future and several innovative technological projects will be shared by speakers from all over the globe.

These are just some of the topics that will be tackled at the World Hospital Congress on 10-12 October in Brisbane, Australia. View the full program here.

The early bird registration ends on 30 June. For more information about the Congress and to register visit: www.hospitalcongress2018.com

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:20How healthcare needs to evolve? Learn from 40+ sessions at IHF’s World Hospital Congress

Drug effective in reducing glucocorticoid-induced bone loss

, 26 August 2020/in E-News /by 3wmedia

About one in every 100 people in the world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect — they induce the bone loss called osteoporosis, causing an estimated yearly bone fracture rate of 5 percent.
An alternative treatment option now appears promising, according to results of an international study. The study was headed by Kenneth Saag, M.D., the Jane Knight Lowe Professor of Medicine at the University of Alabama at Birmingham.
Saag and colleagues compared the monoclonal antibody denosumab against a standard treatment for glucocorticoid-induced secondary osteoporosis, the bisphosphonate risedronate. In the 12-month results of their 24-month study, they have found that denosumab was superior to risedronate, as measured by increased bone density in the lower spine.
“To our knowledge, ours is the first large, randomized controlled trial of denosumab in patients with glucocorticoid-induced osteoporosis who were either prevalent glucocorticoid users or newly initiating glucocorticoid therapy,” they wrote. “Denosumab could be a useful addition to the treatment armamentarium for glucocorticoid-induced osteoporosis.”
The double-blind study enrolled 795 patients at 79 health care centres in Europe, Latin America, Asia and North America. Of these, 505 were glucocorticoid-continuing patients who had received glucocorticoids for at least three months, and 290 were glucocorticoid-initiating patients who had received glucocorticoids for less than three months.
Glucocorticoids, such as prednisone, have a side effect — they induce the bone loss called osteoporosis, causing an estimated yearly bone fracture rate of 5 percent.
Patients were randomly assigned to one of two groups. The denosumab group got a shot of denosumab underneath the skin every six months and took a placebo pill every day. The risedronate group got a placebo shot every six months and took oral risedronate every day.
Besides the superior lumbar spine bone density with denosumab after 12 months, researchers also found that denosumab was superior to risedronate for bone density measured in the total hip and at the neck of the femur, the large bone of the thigh.
The two treatment groups had similar safety profiles.
The researchers note that the study compared denosumab with risedronate, so the relative performance of denosumab compared with osteoporosis treatments besides risedronate has not yet been established.

University of Alabama at Birminghamwww.uab.edu/news/research/item/9372-uab-led-study-shows-drug-effectiveness-in-reducing-glucocorticoid-induced-bone-loss
 

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:28Drug effective in reducing glucocorticoid-induced bone loss

Computer-aided facial analysis helps diagnosis

, 26 August 2020/in E-News /by 3wmedia

In rare diseases, the computer-aided image analysis of patient portraits can facilitate and significantly improve diagnosis. This is demonstrated by an international team of scientists under the leadership of the University Hospital Bonn and the Charité – Universitätsmedizin Berlin on the basis of so-called GPI anchor deficiencies. Using data on genetic material, cell surface texture and typical facial features, researchers utilized artificial intelligence methods to simulate disease models. The results may also be ground-breaking for other diseases.
Mabry syndrome is a rare disease that causes mental retardation. It is triggered by a change in a single gene. “This disease belongs to a group that we describe as GPI anchor deficiencies and which includes more than 30 genes”, explains physician and physicist Prof. Dr. Peter Krawitz from the Institute for Genome Statistics and Bioinformatics of the University Hospital Bonn. GPI is the abbreviation for glycosylphosphatidylinositol. GPI anchors attach specific proteins to the cell membrane. If this does not work properly due to a gene mutation, signal transmission and further steps in the cell-cell communication are impaired.
The spectrum of the external appearance of GPI anchor deficiencies is very broad: The clinical impact of a mutation in a particular gene can range from mild to profound. This also applies to distinctive facial features. In Mabry syndrome for example, a narrow, sometimes tent-shaped upper lip, broad bridge of the nose and wide-set eyes with long palpebral fissures are among the classic features, but these may be more or less pronounced. This often complicates the diagnosis of this rare disease. The elevated alkaline phosphatase (AP) levels in the blood which are also considered characteristic for the syndrome cannot be detected in every patient. “The result is that many patients and their relatives often suffer many years of uncertainty until the correct diagnosis is made”, says Krawitz.
An international research team led by Dr. Alexej Knaus and Prof. Krawitz from the Institute for Genome Statistics and Bioinformatics of the University Hospital Bonn and Prof. Dr. Denise Horn from the Institute of Medical Genetics and Human Genetics of the Charité investigated how the diagnosis of GPI anchor deficiencies can be improved with the help of modern, particularly fast DNA sequencing methods, cell surface analysis and computer-aided image recognition (next-generation phenotyping).
The researchers applied artificial intelligence in image analysis
In the large-scale overview study, the scientists used photographs of the faces of a total of 91 patients. Cell surface changes characteristic for GPI anchor deficiencies were detected in some of the participants. Genetic analysis also revealed gene mutations that are typical for this rare group of diseases. “The artificial modelling of gene-typical faces that we achieved with these datasets clearly shows that the computer-aided evaluation of patients’ portraits can facilitate and improve the diagnosis of GPI anchor deficiencies, which is significant progress”, says lead author Dr. Knaus.
With the assistance of combined data from the laboratory and the computer, the authors hope to gain better understanding of the molecular processes involved in such diseases. For example, it was shown that increased blood alkaline phosphatase levels and conspicuous image analysis results provide a reliable indication of a new mutation in a GPI anchor deficiency. Because of the shared molecular causes shown during the research and the similarity of the patients that has now been quantified, Krawitz also advocates using the term “GPI anchor deficiency” for this group of diseases.
Bonn Universityhttps://tinyurl.com/ycq27csx

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:35Computer-aided facial analysis helps diagnosis

Spinal tap needle type impacts the risk of complications

, 26 August 2020/in E-News /by 3wmedia

The type of needle used during a lumbar puncture makes a significant difference in the subsequent occurrence of headache, nerve irritation and hearing disturbance in patients, according to a study by McMaster researchers.
As well, they found the pencil-point atraumatic needle with the better tip design has been available for about 70 years, but few physicians have been using it because they have not been aware of its benefits over the conventional bevelled traumatic needles.
The implications on clinical care are huge, said Dr. Saleh Almenawer, the senior author of the study and a neurosurgeon at Hamilton Health Sciences who worked with a team of researchers at McMaster University including Sheila Singh, Alex Koziarz and Siddharth Nath.
“There is a more than 50 per cent reduction in the occurrence of headaches with the atraumatic needles, and also more than a 50 per cent reduction in patient readmissions and return to emergency rooms for narcotics or blood patches,” said Almenawer.
Post-dural puncture headaches appear in about 35 per cent of patients, sometimes causing debilitating pain that can lead to a return to hospital for painkillers or more invasive treatment.
The study says using atraumatic needles rather than conventional traumatic needles for lumbar punctures is just as effective and results in a significant decrease in complications such as the headaches.
“The two needles differ in how they penetrate the thick membrane, called the dura, surrounding the nerves,” said Almenawer.
He explained that the sharp edges of the tip of a conventional needle cuts its way through, while the tip of an atraumatic needle causes the tissue to dilate and contract around it. The tiny hole left in the dura by the atraumatic needle makes it significantly more difficult for cerebrospinal fluid to leak through, thus diminishing the frequency of headaches, readmissions and treatment.
Atraumatic needles have been around for decades, but their use remains significantly limited, according to the researchers. They also found the atraumatic needles cost the same or up to three times as much as the more conventional type.
“Several surveys from around the world showed that only a fraction of physicians know atraumatic needles exist, and among those even a smaller portion use the atraumatic type,” said Almenawer.
McMasters Universityhttps://tinyurl.com/y9qmsmm6

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:43Spinal tap needle type impacts the risk of complications

Continuous glucose monitors warn of low blood sugar threat

, 26 August 2020/in E-News /by 3wmedia

Continuous glucose monitors (CGM) can protect individuals who have had type 1 diabetes for years and are at risk of experiencing dangerously low blood sugar by increasing their awareness of the symptoms, according to a study.
Episodes of low blood sugar, known as hypoglycemia, are a major barrier to achieving glycemic control for people with diabetes.
The study’s publication comes as the Endocrine Society is developing a multi-year, multi-stakeholder initiative to improve understanding of hypoglycemia and reduce associated costs by implementing strategies to improve prevention and surveillance.
Severe hypoglycemia can cause seizures, loss of consciousness and death. Hypoglycemia linked to the use of insulin was responsible for an estimated $600 million (£510 million) in emergency room visits between 2007 and 2011.
“In individuals who have repeatedly experienced hypoglycemia, the body blunts awareness of symptoms warning of impending episodes,” said the study’s first author, Michael R. Rickels, M.D., M.S., of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, Pa. “Wearing a continuous glucose monitor that flags falling glucose levels and has built-in alarms raises recognition of the threat.”
Eleven individuals who had been diagnosed with type 1 diabetes for at least 10 years and had impaired awareness of hypoglycemia received CGMs to monitor their blood sugar levels during an 18-month period. The researchers found the participants became more aware of hypoglycemia events and were less likely to experience severe hypoglycemic episodes after they started using CGMs. However, the body’s defence mechanisms against developing low blood sugar remained impaired. The participants’ hemoglobin A1c levels, which track average blood glucose over time, did not change.
“While the body’s own defences against hypoglycemia did not improve, CGMs filled a valuable need in alerting individuals to oncoming episodes,” Rickels said. “In the absence of physiologic defences against the development of low blood glucose, near-constant use of continuous glucose monitoring may be required to minimize the burden of problematic hypoglycemia in patients with long-standing type 1 diabetes.”
The Endocrine Society and its 18 partners in the Hypoglycemia Quality Collaborative identified reducing and preventing the condition as a high priority.
The Society’s new hypoglycemia quality initiative aims to improve outcomes in individuals with type 2 diabetes. The project’s goals include decreasing the frequency and severity of hypoglycemia episodes, identifying patients who are at high risk in a timely manner, and supporting appropriate clinical interventions that can be administered in doctors’ offices and clinics, avoiding the need for hospitalization. The effort brings together stakeholders from industry, nonprofit organizations and patient groups.

Endocrine Societyhttps://tinyurl.com/yar6t4wb

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:23Continuous glucose monitors warn of low blood sugar threat

Fewer adverse side-effects from partial or reduced breast radiotherapy

, 26 August 2020/in E-News /by 3wmedia

Breast cancer patients reported fewer moderate or marked side effects if they were treated with radiotherapy to part of the breast or a reduced dose to the whole breast, according to new findings from a major study.
The IMPORT LOW study of 2,016 women in 41 centres in the UK has already shown that partial breast and reduced dose radiotherapy was as effective as whole breast radiotherapy in controlling the cancer at five years, and women in the partial breast and reduced dose groups reported fewer side-effects, including less change in the appearance of the breast.
These latest results, which focus predominantly on side-effects affecting the breast and also body image reported during the five years following radiotherapy, show that over half of patients in the study did not report moderate or marked side-effects at any point and that most side-effects reduced over time.
The number of side-effects reported per person were fewer in the partial breast and reduced dose groups compared with the whole breast radiotherapy group.
The IMPORT LOW trial was coordinated by the Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, and funded by Cancer Research UK.
The Institute of Cancer Researchwww.icr.ac.uk/news-archive/women-report-fewer-adverse-side-effects-from-partial-or-reduced-breast-radiotherapy-reveals-major-study

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:30Fewer adverse side-effects from partial or reduced breast radiotherapy

Gentle diagnostics make early-stage heart disease visible

, 26 August 2020/in E-News /by 3wmedia

By no means are only elderly people at risk from heart diseases. Physically active individuals can also be affected, for example if a seemingly harmless flu bug spreads to the heart muscle. Should this remain undetected and if, for example, a builder continues with his strenuous job or an athlete carries on training, this can lead to chronic inflammation and in the worst case even to sudden death.
Professor Eike Nagel and his 12 co-workers at the Institute for Experimental and Translational Cardio Vascular Imaging of Goethe University Frankfurt are developing better ways to predict and diagnose heart diseases. In recent years, the researchers have taken the lead in the development of a procedure that is still very new in heart scans. Nagel explains the advantages: “With the help of magnetic resonance imaging, we can look right inside the heart muscle.” Blood flow to the heart muscle is visualized and shows whether there are any constrictions of the arteries supplying the heart. Experts can also spot whether the heart muscle is scarred, inflamed or displays any other anomalies.
The comparatively fast method makes it possible to examine patients at an early stage and may prevent cardiac insufficiency or even a heart attack. “Diseases such as HIV, kidney damage, rheumatic diseases or tumours often affect the heart either directly or as a side effect of therapy,” says Nagel, describing groups potentially at risk. The cardiologist is convinced: “Nowadays we can treat or even cure so many diseases, but the heart suffers too and this should be carefully monitored as it mostly remains undetected.”
MRI is a non-invasive and gentle examination technique, which is less risky but just as efficient as an examination using a conventional heart catheter, where a thin tube is pushed in the direction of the heart through an artery. Nagel’s research group was recently able to demonstrate this in a large international multi-centre study that was met with international acclaim.
The Institute for Experimental and Translational Cardio Vascular Imaging also has state-of-the-art computer tomography equipment at its disposal that can produce three-dimensional images of the heart. These especially reveal calcium deposits and plaques in the artery walls which could rupture and trigger a sudden heart attack. “This allows us to determine the risk of a heart attack and the need for therapy fast and at an early stage, which can then be non-invasive,” says Nagel. Which technique is best for which patient is one of the research topics Nagel’s group is evaluating. In some patients, both may be needed and the Institute is optimally equipped to answer most aspects of heart disease thanks to its deep insight into the heart.
Nagel finds these rapid advances in imaging over the last decades fascinating: “Nowadays we can spot the slightest changes and literally get a clear picture of the heart’s condition.”
Goethe Universitäthttps://tinyurl.com/ycvjvutf

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:38Gentle diagnostics make early-stage heart disease visible

Study paves the way for better treatment of prostate cancer

, 26 August 2020/in E-News /by 3wmedia

A new study has found a way to identify men with locally advanced prostate cancer who are less likely to respond well to radiotherapy.
Led by Professor Catharine West, The University of Manchester team created a method of selecting prostate cancer patients who would benefit from treatments which target oxygen deficient tumours.
The study was funded by Prostate Cancer UK Prostate Cancer UK with support from the Movember Foundation, and NIHR Manchester Biomedical Research Centre and published in eBiomedicine .
Tumour hypoxia is associated with a poor prognosis in prostate cancer: the lower the oxygen, the greater the resistance to treatment and the more likely a tumour will spread.
The researchers identified a 28-gene signature, which accurately identifies hypoxic tumour tissue in patients with prostate cancer which invades nearby structures
The signature was derived using analysis of human cells in the lab and patient survival data.
The signature was validated using data from across the world in eleven prostate cancer cohorts and a bladder cancer phase III randomized trial of radiotherapy.
According to cancer.net, the 5-year survival rate for most men with local prostate cancer is almost 100%. 98% are alive after 10 years, and 96% live for at least 15 years.
For men diagnosed with prostate cancer that has spread nearby, the 5-year survival is around 70%.

“Until now, there has been no clinically validated method of selecting prostate cancer patients who would benefit from hypoxia modifying treatment
Professor Catharine West„

For men diagnosed with prostate cancer that has spread to other parts of the body, the 5-year survival rate is 29%.
According to Cancer Research UK , over 11,000 still die from the disease every year. In 2014, 13% of all male cancer deaths were from prostate cancer.
Professor West is based at the Manchester Cancer Research Centre- a world renowned partnership between The University of Manchester, The Christie NHS Foundation Trust and Cancer Research UK.
She said: “Ninety percent of prostate cancer patients are diagnosed with localised cancer, which have a highly variable course of disease progression.
“And we know that combining hypoxia-targeting treatment with radiotherapy has been shown to improve local control of tumours and survival of patients in head and neck and bladder cancers.”
She added: “This study has built on work to identify possible ways for measuring hypoxia in prostate cancer using gene signatures.
“Until now, there has been no clinically validated method of selecting prostate cancer patients who would benefit from hypoxia modifying treatment.

University of Manchesterwww.manchester.ac.uk/discover/news/study-paves-the-way-for-better-treatment-of-prostate-cancer/

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:25Study paves the way for better treatment of prostate cancer

New blood pressure app and hardware rivals arm cuff accuracy

, 26 August 2020/in E-News /by 3wmedia

Cuff devices for blood pressure measurement are inconvenient, and mobile device apps for blood pressure measurement that are now being introduced may lack accuracy.
To solve this problem, a team of Michigan State University scientists have created a new app and hardware for smartphones to measure blood pressure with accuracy that may rival arm-cuff devices. The technology also includes a discovery of a more convenient measurement point.
“We targeted a different artery, the transverse palmer arch artery at the fingertip, to give us better control of the measurement,” said Anand Chandrasekhar, MSU electrical and computer engineering doctoral student and the lead author. “We were excited when we validated this location. Being able to use your fingertip makes our approach much easier and more accessible.”
The approach uses two sensors: an optical sensor on top of a force sensor. The sensor unit and other circuitry are housed in a 1 centimetre-thick case attached to the back of the phone. Users turn on the app and press their fingertip against the sensor unit. With their finger on the unit, they hold their phone at heart level and watch their smartphone screen to ensure they’re applying the correct amount of finger pressure.
“A key point was to see if users could properly apply the finger pressure over time, which lasts as long as an arm-cuff measurement,” Ramakrishna Mukkamala, MSU electrical and computer engineering professor and senior author said. “We were pleased to see that 90 percent of the people trying it were able to do it easily after just one or two practice tries.”
Internationally, this device could be a game-changer. While high blood pressure is treatable with lifestyle changes and medication, only around 20 percent of people with hypertension have their condition under control. This invention gives patients a convenient option, and keeping a log of daily measurements would produce an accurate average, discounting an occasional measurement anomaly, Mukkamala added.
The research team will continue to improve accuracy and hopes to pursue more comprehensive testing based on the standard protocol of the Association for the Advancement of Medical Instrumentation. The scientists are already making inroads to build improved hardware. Future iterations could be as thin as 1 millimetre and be part of a standard protective phone case.
Michigan State Universitymsutoday.msu.edu/news/2018/new-blood-pressure-app-and-hardware-rivals-arm-cuff-accuracy/

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:33New blood pressure app and hardware rivals arm cuff accuracy

Canon Medical Systems Corporation receives Green Apple Environmental best practice award

, 26 August 2020/in E-News /by 3wmedia

Canon Medical Systems Corporation (formerly Toshiba Medical) has been awarded the Green Apple Environmental best practice award. The Green Apple awards, a Green Organisation initiative, are part of an annual international campaign to recognise, reward and promote environmental best practice around the world. Canon Medical Systems Corporation was proclaimed Gold Winner in the category Innovation, for its Aquilion ONE Genesis CT scanner. The exclusive awards ceremony was held in the Palace of Westminster, London. Awards were presented in various categories, such as Carbon, Energy Efficiency, Manufacturing and Waste management.

The award winning CT Scanner, Aquilion ONE Genesis, is a smaller and lighter Premium CT system than its predecessors, thus requiring less power. Designed for an installation space of just 19 m2, Aquilion ONE Genesis Edition can be installed in most existing CT rooms, avoiding costly renovations. The open Gantry structure with short bore facilitates access from the front and rear of the gantry.

With regard to the exposure dose for the patients, Aquilion ONE Genesis applies the latest dose reduction technologies and reconstruction algorithms, such as PUREViSION detector technology and FIRST. Its advanced detector technology converts almost 100% of incident X-ray photons for maximum dose efficiency. FIRST is the world’s first fully integrated Iterative Reconstruction Technology in Premium CT, resulting in the lowest dose levels technically achievable today.
 
Henk Zomer, Senior Manager Computed Tomography, says: “It is a great honour for us to receive this award, that shows that Canon Medical’s environmentally innovative products are highly rated internationally. We endeavour to contribute to society with our medical systems while improving the efficiency of medical services, and we vigorously promote our environmental conservation activities.”

“Green Apple Awards” are a prestigious global recognition of environmental best practice issued by “The Green Organisation” – an international, independent, non-profit, non-political, non-activist environment group that was established in 1994 to recognize, reward and promote environmental best practice around the world.

https://eu.medical.canon 
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:40Canon Medical Systems Corporation receives Green Apple Environmental best practice award
Page 205 of 228«‹203204205206207›»

Latest issue of International Hospital

April 2024

9 May 2025

New open-source AI platform launched for global infectious disease surveillance

9 May 2025

Fujifilm launches advanced ELUXEO 8000 endoscopy system in Europe

5 May 2025

Siemens Healthineers unveils helium-independent MRI system for radiotherapy

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription